Navigation Links
Macroglobulinemia in Medical News

GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

...d with chlorambucil in patients with previously untreated CLL. In NHL, an ongoing Phase II study will assess ofatumumab in patients with Waldenstrom's macroglobulinemia - a rare type of slow-growing NHL.(8) Finally, a Phase II study is evaluating ofatumumab plus ICE or DHAP chemotherapy regimen in relapsed/refractory ...

Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology

...ER 6th Abstract 1010 TITLE: Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom macroglobulinemia (WM) Session Name: Biologic Therapies for NHL (Excluding Pre-clinical Models) Presentation Time: 5:30 PM - 7:30 PM Location: Moscone Center, Hall...

Risk of Lymphoma Increases With Hepatitis C Virus Infection

...nd that HCV infection increased the risk of developing non-Hodgkin's lymphoma by 20 percent to 30 percent. The risk of developing Waldenstrm's macroglobulinemia (a rare type of non-Hodgkin's lymphoma) went up by 300 percent and the risk for cryoglobulinemia, a condition marked by abnormal levels of certain ant...
Macroglobulinemia in Medical Technology

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology

Dr. Irene Ghobrial of the Dana-Farber Cancer Institute presents phase 2 results demonstrating the single agent clinical activity of perifosine in patients with relapsed / refractory Waldenstroms Macroglobulinemia NEW YORK, June 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nas...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

Data presented at the 11th International Myeloma Workshop held in Kos, Greece demonstrates clinical activity of perifosine in combination with bortezomib, dexamethasone and lenalidomide plus dexamethasone, in patients with relapsed/refractory multiple myeloma, and as a single agent in patients with...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

...l Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom's macroglobulinemia (WM) Single agent perifosine achieved a 36% ORR (MR, PR) and 58% stable disease in a heavily pre-treated Waldenstrom's macroglobulinemia patient population. Clinical benefit was demonstrated as reflected by a me...

New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia

...Centers-Midtown: Phase II study of oral Panobinostat in adult patients with advanced refractory multiple myeloma Waldenstrom macroglobulinemia Jeffrey Matous, M.D., Rocky Mountain Cancer Centers-Midtown: Phase II trial of combination of Bortezomib and Rituximab in relapsed...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

...ferent underlying anemias will also be presented RAD001 data demonstrating benefit in patients with relapsed and/or refractory Waldenstrom macroglobulinemia (ASH Abstract #1011 ; Saturday, December 6, 2008; 5:30 - 7:30 PM PST) More than 10 abstracts on p anobinostat ( LBH589 ), showing e...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

....D., Rocky Mountain Cancer Centers-Rose, and John Mattern, D.O., Virginia Oncology Associates-Newport News: Primary therapy of Waldenstrom's macroglobulinemia with bortezomib, dexamethasone and rituximab: results of WMCTG Clinical Trial 05-180 About US Oncology Research The US Oncology Research netw...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

... Phase 2 Results of Perifosine in the Treatment of Patients with Relapsed/Refractory Waldenstrom's macroglobulinemia to be presented Tomorrow, Tuesday, June 3rd at 12:00pm in Room E450a NEW YORK, June 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, I...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

...established agents in patients with relapsed MCL, indolent NHL and Waldenstrom's Macroglobulinemia, including: -- Primary therapy of Waldenstrom's macroglobulinemia with bortezomib, dexamethasone and rituximab: results of WMCTG clinical trial 05-180 -- Lead investigator: Steven Treon, M.D., Ph.D., Assistan...

Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting

...7:45am; McCormick Place Convention Center, E Arie Crown Theater Oral Presentation: Long-term responses to thalidomide and rituximab in Waldenstrom's macroglobulinemia -- J. Soumera; Abstract #8017; June 3, 2007; 1:00-1:15pm; McCormick Place Convention Center, E354b Oral Presentation: Impact of prior thalidomide (T...

Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75

...ace Convention Center, S HallA2 Data Presented Sunday, June 3 Oral Presentation: Long-term responses to thalidomide and rituximab in Waldenstrom's macroglobulinemia -- J. Soumera; Abstract #8017; June 3, 2007; 1:00-1:15 pm; McCormick Place Convention Center, E354b Oral Presentation: Impact of prior thalidomide (...
Macroglobulinemia in Biological News

Risk of lymphoma increases with hepatitis C virus infection

...ne, found that HCV infection increased the risk of developing non-Hodgkin's lymphoma by 20 percent to 30 percent. The risk of developing Waldenström's macroglobulinemia (a rare type of non-Hodgkin's lymphoma) went up by 300 percent and the risk for cryoglobulinemia, a condition marked by abnormal levels of certain ant...
Macroglobulinemia in Biological Technology

The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research

WHITE PLAINS, N.Y., July 6 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and The International Waldenstrom's Macroglobulinemia Foundation (IWMF) have partnered in an initiative to develop stable and immortalized Waldenstrom's macroglobulinemia (WM) cell lines that would be made widely ...

Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan

...atory studies of perifosine as a treatment for the following tumor types: renal cell, colon, hepatocellular, multiple myeloma, waldenstrom's macroglobulinemia and sarcoma; -- terminating our license agreement for KRX-0601 (UCN-01); and -- closing the Company's San Francisco, California and Memphis, Ten...

Proteolix's Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma

...more information on multiple myeloma go to http://www.cancer.gov/cancertopics/types/myeloma . About Waldenstrom's Macroglobulinemia Waldenstrom's macroglobulinemia (WM) is a slow-growing type of non-Hodgkin's lymphoma that starts in white blood cells called B lymphocytes. WM is also called lymphoplasmacytic lymph...
Other Tags
(Date:4/23/2014)... the potential health benefits of probiotics, antioxidants and other ... And the chemical industry is getting in on the ... deter growth, so the industry is responding with clinical ... cover story in Chemical & Engineering News ... Society. , Melody M. Bomgardner, a senior editor at ...
(Date:4/23/2014)... about an increase in adolescents, marijuana use following the ... relief. According to a new study at Rhode Island ... states with and without medical marijuana laws, legalizing the ... The study is published online in advance of print ... , "Any time a state considers legalizing medical marijuana, ...
(Date:4/23/2014)... Getting to the bottom of Alzheimer,s disease has ... turns and controversies. In the latest crook in ... insight into the interaction between proteins associated with ... journal ACS Chemical Neuroscience , could have ... K. Surewicz, Krzysztof Nieznanski and colleagues explain that ...
(Date:4/22/2014)... can provide primary care for low-income patients may ... insurance companies while improving patient health, researchers have ... that health clinics that avoid costs associated with ... lowering hospital admission rates and emergency room visits, ... State Altoona. , The researchers estimated that ...
(Date:4/22/2014)... The International Communication Association will hold its 64th ... theme of the 2014 conference will explore what ... digital society. , Featuring over 2,300 academic papers ... scholars representing over 40 countries, the ICA conference ... the world. This year,s conference features sessions that ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
(Date:4/22/2014)... As President Barack Obama begins a trip to ... strategic pivot to the Pacific, officials at the ... Asia-Pacific Technology and Education Partnership (APTEP) as an ... United States and its allies in the region. ... partnerships across the Asia-Pacific region, supports the development ...
(Date:4/22/2014)... news release is available in French . ... than a month, sequencing of the complete genome and ... Guinea forms a clade (variant) that is distinct from ... and in Gabon. Epidemiological investigations also linked the laboratory ... December 2013 outbreak. , Ebola virus is a lethal, ...
(Date:4/22/2014)... exposure to environmental enrichment can induce neurogenesis ... and memory. Previous studies have demonstrated that ... superficial layer of the cerebral cortex of ... these neurons exhibit very weak properties of ... environmental enrichment has an impact on the ...
Breaking Biology News(10 mins):Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2
Other Contents